Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.
Elyse Lower, MD
Advertisement
Articles by Elyse Lower, MD
Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Lower on the Impact of Tucatinib on HER2+ Breast CancerPublished: May 17th 2021 | Updated:
Dr. Lower on the Importance of Tucatinib Plus Capecitabine/Trastuzumab in HER2+ Breast CancerPublished: June 2nd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5